Atlas Trials

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Clinical trial NCT03870880 · COMPLETED

Trial details

NCT number
NCT03870880
Sponsor
Rovi Pharmaceuticals Laboratories
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2017-08-25
Primary completion
2020-01-08
Enrollment
215

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.